Benzinga

Benzinga

Benzinga

miércoles, septiembre 02

Revolution Medicines Inc

RVMDNASDAQ
Trade with Public
Trade with Public
$210.60
0.730.35%
Últ. Act.: Sep 2, 9:29 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Revolution Medicines Financials

Revolution Medicines (RVMD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(3.06) per share which missed the analyst consensus estimate of $(1.98) by 54.55 percent. This is a 133.59 percent decrease over losses of $(1.31) per
Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Revolution Medicines Sees FY26 GAAP Operating Expenses $1.7B-$1.8B

Benzinga Newsdesk

PRO
Revolution Medicines Q1 EPS $(2.29) Misses $(1.82) Estimate

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(2.29) per share which missed the analyst consensus estimate of $(1.82) by 25.82 percent. This is a 102.65 percent decrease over losses of $(1.13) per
Benzinga Newsdesk

Revolution Medicines: Q4 Earnings Insights

Benzinga Insights

PRO
Revolution Medicines Q4 EPS $(1.86) Misses $(1.58) Estimate. Cash And Equivalents $2.03B

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.86) per share which missed the analyst consensus estimate of $(1.58) by 17.87 percent. This is a 66.07 percent decrease over losses of $(1.12) per share
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved